- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00535496
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
Comparison of the T4/T1 Ratio Measured by Means of the TOF Watch® SX With the Reappearance of T4 Measured by Means of a Peripheral Nerve Stimulator in Adult Subjects Receiving 4.0 mg.Kg-1 Sugammadex at 15 Minutes After Rocuronium
Study Overview
Detailed Description
The TOF-Watch® SX has been used for neuromuscular monitoring in all
clinical trials with sugammadex. In clinical practice however, a PNS is commonly
used in many hospitals worldwide. A disadvantage of a PNS is that it is not objective monitoring like the TOF-Watch® SX, and it can detect only the number of twitches. In this trial, the relationship between the time to reappearance of T4 using PNS (i.e. Ministim® model MS-IV) and the time to recovery of the T4/T1 ratio to 0.9 using the TOF-Watch® SX was determined after a dose of 4.0 mg/kg sugammadex was administered 15 minutes after the last dose of rocuronium. Determining this relationship will enable the provision of advice on when it is safe to extubate participants after administration of 4.0 mg/kg sugammadex for reversing neuromuscular block while using a PNS. The time to reappearance of T4 was assessed by a blinded PNS-assessor. This assessor was blinded for the dose of sugammadex used and for the TOF results measured with the TOF-Watch® SX.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) Class 1 or 2 or 3
- between the ages of 18 to 64 years, inclusive
- scheduled for a surgical procedure under general anesthesia requiring
neuromuscular relaxation with the use of rocuronium
- scheduled for a surgical procedure in supine position
- have given written informed consent
Exclusion Criteria:
- participants with a difficult intubation because of expected anatomical
malformations
- known or suspected to have neuromuscular disorders impairing
neuromuscular blockade and/or significant hepatic and/or renal
dysfunction
- medical or physical condition that is expected to interfere
with the proper conduct of simultaneous neuromuscular monitoring on
both arms
- known or suspected to have a (family) history of malignant
hyperthermia
- known or suspected to have arthritis or another disease that will
cause the thumb not to move freely
- known or suspected to have an allergy to narcotics, muscle
relaxants or other medication used during general anesthesia
- is receiving medication in a dose and/or at a time point known to
interfere with neuromuscular blocking agents (NMBAs), such as antibiotics, anticonvulsants and Mg2+
- already participated in a sugammadex trial
- participated in another clinical trial, not pre-approved, within prior 30 days
- pregnant females
- breast-feeding females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
|
Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary.
Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Other Names:
|
Experimental: 2
sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
|
Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary.
Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Other Names:
|
Experimental: 3
sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
|
Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary.
Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Other Names:
|
Experimental: 4
sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
|
Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary.
Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time From Start of Administration of 4.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.9 Measured by a TOF-Watch® SX
Time Frame: Up to 4 minutes after administering sugammadex
|
Neuromuscular function was monitored by applying repetitive TOF electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle with the TOF-Watch® SX.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.9.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
Only participants treated with 4.0 mg/kg sugammadex are presented, where the TOF-Watch® SX on the dominant forearm n =30, and on the non-dominant forearm n = 31.
The 1.0 mg/kg sugammadex group was not evaluated for this outcome measure.
|
Up to 4 minutes after administering sugammadex
|
Time From Start of Administration of 4.0 mg/kg Sugammadex to Reappearance of T4 Measured by a Peripheral Nerve Stimulator (PNS)
Time Frame: up to 2 minutes after administering sugammadex
|
Neuromuscular function was monitored with a PNS by applying repetitive TOF stimulation to the ulnar nerve of one forearm every 15 seconds and assessing the number of twitches at the adductor pollicis muscle by a blinded PNS assessor.
T4 is the fourth twitch after TOF nerve stimulation.
Only participants treated with 4.0 mg/kg sugammadex are presented, where the PNS on the dominant forearm n =31, and on the non-dominant forearm n = 30.
The 1.0 mg/kg sugammadex group was not evaluated for this outcome measure.
|
up to 2 minutes after administering sugammadex
|
Difference in Time Between Recovery of T4/T1 Ratio to 0.9 as Measured by TOF Watch® SX, and Reappearance of T4 as Measured by PNS, Within Participants, After Administration of 4.0 mg/kg Sugammadex
Time Frame: Up to 3 minutes after administering sugammadex
|
The difference between the recovery of T4/T1 ratio to 0.9 and reappearance of T4 within participants was assessed from an ANOVA method.
Only participants treated with 4.0 mg/kg sugammadex are presented, where the TOF-Watch® SX on the dominant forearm n =30, and on the non-dominant forearm n = 31; and the PNS on the dominant forearm n =31, and on the non-dominant forearm n = 30.
The 1.0 mg/kg sugammadex group was not evaluated for this outcome measure.
|
Up to 3 minutes after administering sugammadex
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time From Start of Administration of 1.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.9 Measured by a TOF-Watch® SX
Time Frame: Up to 150 minutes after administering sugammadex
|
Neuromuscular function was monitored by applying repetitive TOF electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle with the TOF-Watch® SX.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.9.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
Only participants treated with 1.0 mg/kg sugammadex are presented where the TOF-Watch® SX on the dominant forearm n =15, and on the non-dominant forearm n = 14.
The 4.0 mg/kg sugammadex group was not evaluated for this outcome measure.
|
Up to 150 minutes after administering sugammadex
|
Time From Start of Administration of 1.0 or 4.0 mg/kg Sugammadex to Reappearance of T4 Measured by a TOF-Watch® SX
Time Frame: Up to 7 minutes after administering sugammadex
|
Neuromuscular function was monitored by applying repetitive TOF electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle with the TOF-Watch® SX.
T4 is the fourth twitch after TOF nerve stimulation.
For participants treated with 1.0 mg/kg sugammadex the TOF-Watch® SX on the dominant forearm n =15, and on the non-dominant forearm n = 14.
For participants treated with 4.0 mg/kg sugammadex the TOF-Watch® SX on the dominant forearm n =30, and on the non-dominant forearm n = 31.
|
Up to 7 minutes after administering sugammadex
|
Time From Start of Administration of 1.0 mg/kg Sugammadex to Reappearance of T4 Measured by a PNS
Time Frame: Up to 5 minutes after administering sugammadex
|
Neuromuscular function was monitored by applying repetitive TOF stimulations manually to the ulnar nerve of one forearm every 15 seconds & the number of twitches collected manually at the adductor pollicis muscle with the PNS by a blinded PNS assessor.
T4 is the fourth twitch after TOF nerve stimulation.
Only participants treated with 1.0 mg/kg sugammadex are presented, where the PNS on the dominant forearm n =15, and on the non-dominant forearm n = 14.
The 4.0 mg/kg sugammadex group was not evaluated for this outcome measure.
|
Up to 5 minutes after administering sugammadex
|
Time From Start of Administration of 1.0 or 4.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.8 Measured by a TOF-Watch® SX
Time Frame: Up to 42 minutes after administering sugammadex
|
Neuromuscular function was monitored by applying repetitive TOF electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle with the TOF-Watch® SX.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.8.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
For participants treated with 1.0 mg/kg sugammadex the TOF-Watch® SX on the dominant forearm n =15, and on the non-dominant forearm n = 14.
For participants treated with 4.0 mg/kg sugammadex the TOF-Watch® SX on the dominant forearm n =30, and on the non-dominant forearm n = 31.
|
Up to 42 minutes after administering sugammadex
|
Time From Start of Administration of 1.0 or 4.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.7 Measured by a TOF-Watch® SX
Time Frame: Up to 42 minutes after administering sugammadex
|
Neuromuscular function was monitored by applying repetitive TOF electrical stimulations with the TOF-Watch® SX to the ulnar nerve of one forearm every 15 seconds & assessing twitch response at the adductor pollicis muscle with the TOF-Watch® SX.
T1 and T4 are the magnitudes (heights) of the first and fourth twitches respectively after TOF nerve stimulation, where stimulation was continued until the T4/T1 ratio reached 0.7.
A higher T4/T1 ratio indicates a lower degree of neuromuscular blockade, with a value of 1.0 representing full recovery.
For participants treated with 1.0 mg/kg sugammadex the TOF-Watch® SX on the dominant forearm n =15, and on the non-dominant forearm n = 14.
For participants treated with 4.0 mg/kg sugammadex the TOF-Watch® SX on the dominant forearm n =30, and on the non-dominant forearm n = 31.
|
Up to 42 minutes after administering sugammadex
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- P05698
- 19.4.313
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Blockade
-
Hospital Federal de BonsucessoUnknownNeuromuscular Blockade | Magnesium Sulfate | Rocuronium | Deep Neuromuscular BlockadeBrazil
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedNeuromuscular Blockade | Neuromuscular MonitoringItaly
-
Universitair Ziekenhuis BrusselUnknownNeuromuscular Blockade | Neuromuscular MonitoringBelgium
-
Central Hospital, Nancy, FranceNot yet recruitingComparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function (DECURAR-EMG)Neuromuscular BlockadeFrance
-
Vanderbilt University Medical CenterUniversity of Pittsburgh; The Cooper Health SystemRecruitingNeuromuscular BlockadeUnited States
-
Leiden University Medical CenterMerck Sharp & Dohme LLCCompletedNeuromuscular BlockadeNetherlands
-
Seoul National University Bundang HospitalCompleted
-
Poitiers University HospitalEnrolling by invitationNeuromuscular BlockadeFrance
-
Centre Hospitalier Universitaire Dinant Godinne...CompletedNeuromuscular BlockadeBelgium
-
Seoul National University HospitalCompletedNeuromuscular BlockadeKorea, Republic of
Clinical Trials on sugammadex
-
University Health Network, TorontoMerck Sharp & Dohme LLCCompletedPosterior Cervical Decompression and FusionCanada
-
Seoul National University HospitalRecruitingPostoperative Residual CurarizationKorea, Republic of
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCRecruitingPostoperative Urinary RetentionUnited States
-
Severance HospitalCompletedAnesthesia Recovery Period, Neuromuscular BlockadeKorea, Republic of
-
University of AthensUnknownSurgical Procedure, UnspecifiedGreece
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedProstate Cancer | Neuromuscular BlockadeItaly
-
Merck Sharp & Dohme LLCCompletedRenal Insufficiency | Renal ImpairmentUnited States
-
Hopital FochCompleted
-
Beijing Tiantan HospitalCompletedSugammadex | Motor Evoked PotentialsChina
-
Merck Sharp & Dohme LLCCompleted